Bulletin of the World Health Organization

Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles

Roger Ndindjock, Jude Gedeon, Shanthi Mendis, Fred Paccaud & Pascal Bovet

Volume 89, Number 4, April 2011, 286-295

Table 2. Cost of cardiovascular (CV) medications used for selected CV risk management strategies, Seychelles, 2004

Management strategy and medication Cost (2004 US$) per daya
Seychelles India
Single-risk-factor
BP ≥ 140/90 mmHg
   Lisinopril (ACEI) 0.38 0.15
   Atenolol (BB) 0.04 0.04
   Hydrochlorothiazide (D) 0.01 0.03
   Amlodipine (CCB) 0.10 0.04
TSC ≥ 6.2 mmol/l
   Atorvastatin 1.46 0.12
BP ≥ 140/90 mmHg or TSC ≥ 6.2 mmol/l
   Antihypertensives and atorvastatin 1.16 0.18
Total CV risk
CV risk ≥ 10%
     Polypillb 0.26
CV risk ≥ 20%
     Polypillb 0.26
CV risk ≥ 20% or BP ≥ 160/100 mmHg or SC ≥ 8.0 mmol/l
     Polypillb 0.26

ACEI, angiotensin-converting enzyme inhibitor; BB, β-blocker; BP, blood pressure; CCB, calcium channel blocker; D, diuretic; TSC, total serum cholesterol; US$, United States dollars.

a The costs of medications in India and Seychelles were obtained from references Gupta et al.27 and Bovet et al.,20 respectively.

b Composed of aspirin, a statin, a diuretic and an ACEI.